

Please type a ~~plus~~ sign (+) inside this box →



(Use as many sheets as necessary)

Sheet

1

of

1

Application Number	10/802,282
--------------------	------------

10/802,282

Filing Date	March 17, 2004
--------------------	-----------------------

March 17, 2004

First Named Inventor	Woo et al.
----------------------	------------

Woo et al.

Group Art Unit	1623
----------------	------

1623

Examiner Name	Unassigned
---------------	------------

Unassigned

Attorney Docket Number	223467
------------------------	--------

223467

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

342

14

2005/0209172

A1

et al.

Sen 22 2005

[illegible][illegible]

EP

IK

FE

1 514 877

A

Liu et al

Mar 16 2005

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No*

[illegible][illegible]

**Examiner
Signature**

/Elli Peselev/

Date Considered

05/19/2006

- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

SCLOSURE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	1
-------	---	----	---


Application Number	10/802,282
Filing Date	March 17, 2004
First Named Inventor	Woo et al.
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	223467

[illegible]

~~05/19/2006~~

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/802,282
Filing Date	March 17, 2004
First Named Inventor	Woo et al.
Group Art Unit	1623
Examiner Name	Unassigned
Attorney Docket Number	223467

Sheet 1 of 6

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
EP	AU	2,653,899		Bunch et al.	September 29, 1953	
EP	AV	3,417,077		Murphy et al.	December 17, 1968	
EP	AW	3,478,014		Djokic et al.	November 11, 1969	
EP	AX	4,020,270		Arcamone et al.	April 26, 1977	
EP	AY	4,219,641		Desposato et al.	August 26, 1980	
EP	AZ	4,328,334		Kobrehel et al.	May 4, 1982	
EP	BA	4,465,674		Bright et al.	August 14, 1984	
EP	BB	4,474,768		Bright	October 2, 1984	
EP	BC	4,512,982		Hauske et al.	April 23, 1985	
EP	BD	4,517,359		Kobrehel et al.	May 14, 1985	
EP	BE	4,518,590		Hauske et al.	May 21, 1985	
EP	BF	4,526,889		Bright	July 2, 1985	
EP	BG	4,963,531		Remington	October 16, 1990	
EP	BH	5,023,085		Francoeur et al.	June 11, 1991	
EP	BI	5,250,518		Kobrehel et al.	October 5, 1993	
EP	BJ	5,332,807		Waddell et al.	July 26, 1994	
EP	BK	5,441,939		Yang	August 15, 1995	
EP	BL	5,674,911		Emanuele et al.	October 7, 1997	
EP	BM	5,686,587		Yang	November 11, 1997	
EP	BN	5,747,058		Tipton et al.	May 5, 1998	
EP	BO	5,760,010		Klein	June 2, 1998	
EP	BP	5,786,338		Klein	July 28, 1998	
EP	BQ	5,795,871		Narita et al.	August 18, 1998	
EP	BR	5,811,088		Hunter et al.	September 22, 1998	
EP	BS	5,869,629		Bayod Jasanda et al.	February 9, 1999	
EP	BT	5,885,601		Sokal	March 23, 1999	
EP	BU	5,958,888		Macy et al.	September 28, 1999	
EP	BV	6,013,778		Heggie et al.	January 11, 2000	
EP	BW	6,025,350		Masamune et al.	February 15, 2000	
EP	BX	6,043,225		Shor et al.	March 28, 2000	
EP	BY	6,054,133		Horwitz et al.	April 25, 2000	
EP	BZ	6,172,069	B1	Klimstra et al.	January 9, 2001	
EP	CA	6,174,865	B1	Klein	January 16, 2001	
EP	CB	6,218,368	B1	Wirostko	April 17, 2001	
EP	CC	6,239,112	B1	Macy et al.	May 29, 2001	
EP	CD	6,245,903	B1	Karimian et al.	June 12, 2001	
EP	CE	6,281,199	B1	Gupta	August 28, 2001	
EP	CF	6,339,063	B1	Kropp et al.	January 15, 2002	
EP	CG	6,369,035	B1	Kobrehel et al.	April 9, 2002	
EP	CH	6,383,471	B1	Chen et al.	May 7, 2002	

Examiner Signature	<i>Ellen Pescher</i>	Date Considered	5/19/2006
--------------------	----------------------	-----------------	-----------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/802,282
				Filing Date	March 17, 2004
				First Named Inventor	Woo et al.
				Group Art Unit	1623
Examiner Name	Unassigned				
Sheet	2	of	6	Attorney Docket Number	223467

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
CP	CI	6,407,074	B1	Bronk et al.	June 18, 2002	
CP	CJ	6,420,536	B1	Bronk et al.	July 16, 2002	
CP	CK	6,420,537	B1	Bosch et al.	July 16, 2002	
CP	CL	6,451,990	B1	Bayod Jasanada et al.	September 17, 2002	
CP	CM	6,465,437	B1	Rafka et al.	October 15, 2002	
CP	CN	6,500,987	B1	Schwartz et al.	December 31, 2002	
CP	CO	6,504,017	B1	Bosch et al.	January 7, 2003	
CP	CP	6,528,492	B1	de la Torre Garcia et al.	March 4, 2003	
CP	CQ	6,586,576	B2	Aronhime et al.	July 1, 2003	
CP	CR	6,645,528	B1	Straub et al.	November 11, 2003	
CP	CS	6,703,372	B1	Centellas et al.	March 9, 2004	
CP	CT	6,720,001	B2	Chen et al.	April 13, 2004	
CP	CU	6,723,341	B2	Rudnic et al.	April 20, 2004	
CP	CV	6,761,895	B2	Sawada et al.	July 13, 2004	
CP	CW	6,764,997	B2	Tenengauzer et al.	July 20, 2004	
CP	CX	6,777,393	B2	Bronk et al.	August 17, 2004	
CP	CY	6,825,327	B2	Sklavounos et al.	November 30, 2004	
CP	CZ	6,861,413	B2	Li et al.	March 1, 2005	
CP	DA	2001/0014670	A1	Balin et al.	August 16, 2001	
CP	DB	2001/0047089	A1	Aronhime et al.	November 29, 2001	
CP	DC	2001/0048944	A1	Rudnic et al.	December 6, 2001	
CP	DD	2002/0007049	A1	Singer et al.	January 17, 2002	
CP	DE	2002/0012680	A1	Patel et al.	January 31, 2002	
CP	DF	2002/0022054	A1	Sawada et al.	February 21, 2002	
CP	DG	2002/0028920	A1	Lifshitz et al.	March 7, 2002	
CP	DH	2002/0044965	A1	Curatolo et al.	April 18, 2002	
CP	DI	2002/0049167	A1	Abraham et al.	April 25, 2002	
CP	DJ	2002/0061858	A1	Bronk et al.	May 23, 2002	
CP	DK	2002/0071822	A1	Uhrich	June 13, 2002	
CP	DL	2002/0086867	A1	Dubois et al.	July 4, 2002	
CP	DM	2002/0107265	A1	Chen et al.	August 8, 2002	
CP	DN	2002/0111318	A1	Rengaraju	August 15, 2002	
CP	DO	2002/0115621	A1	Su et al.	August 22, 2002	
CP	DP	2002/0142050	A1	Straub et al.	October 3, 2002	
CP	DQ	2002/0143211	A1	Dolitzky et al.	October 3, 2002	
CP	DR	2002/0156026	A1	Bronk et al.	October 24, 2002	
CP	DS	2003/0007958	A1	Chen	January 9, 2003	
CP	DT	2003/0018030	A1	Garti et al.	January 23, 2003	
CP	DU	2003/0050620	A1	Odidi et al.	March 13, 2003	
CP	DV	2003/0064939	A1	Sklavounos et al.	April 3, 2003	

Examiner Signature	<i>E. Kelen</i>	Date Considered	5/19/06
--------------------	-----------------	-----------------	---------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/802,282
				Filing Date	March 17, 2004
				First Named Inventor	Woo et al.
				Group Art Unit	1623
Examiner Name	Unassigned				
Sheet	3	of	6	Attorney Docket Number	223467

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
GP	DW	2003/0092642	A1	Rafka et al.	May 15, 2003	
GP	DX	2003/0104055	A1	Rudnic et al.	June 5, 2003	
GP	DY	2003/0105066	A1	Soldato et al.	June 5, 2003	
GP	DZ	2003/0108597	A1	Chancellor et al.	June 12, 2003	
GP	EA	2003/0119760	A1	Hussain et al.	June 26, 2003	
GP	EB	2003/0119865	A1	Dubois et al.	June 26, 2003	
GP	EC	2003/0139583	A1	Singh et al.	July 24, 2003	
GP	ED	2003/0143259	A1	Roy et al.	July 31, 2003	
GP	EE	2003/0148964	A1	Dunne	August 7, 2003	
GP	EF	2003/0162730	A1	Li et al.	August 28, 2003	
GP	EG	2003/0165563	A1	Murphy et al.	September 4, 2003	
GP	EH	2003/0176369	A1	Tenengauzer et al.	September 18, 2003	
GP	EI	2003/0190365	A1	Fergione et al.	October 9, 2003	
GP	EJ	2003/0206951	A1	Rudnic et al.	November 6, 200	
GP	EK	2003/0207819	A1	Moskowitz	November 6, 2003	
GP	EL	2003/0215496	A1	Patel et al.	November 20, 2003	
GP	EM	2003/0228357	A1	Johnson et al.	December 11, 2003	
GP	EN	2003/0228381	A1	Qazi et al.	December 11, 2003	
GP	EO	2004/0009930	A1	Su et al.	January 15, 2004	
GP	EP	2004/0014951	A1	Dumic et al.	January 22, 2004	
GP	EQ	2004/0014952	A1	Rengaraju	January 22, 2004	
GP	ER	2004/0023896	A1	Bronk et al.	February 5, 2004	
GP	ES	2004/0023898	A1	Dunne	February 5, 2004	
GP	ET	2004/0033969	A1	Burnet et al.	February 19, 2004	
GP	EU	2004/0043944	A1	Li et al.	March 4, 2004	
GP	EV	2004/0043945	A1	Li et al.	March 4, 2004	
GP	EW	2004/0053862	A1	Centellas et al.	March 18, 2004	
GP	EX	2004/0082527	A1	Li et al.	April 29, 2004	
GP	EY	2004/0087517	A1	Burnet et al.	May 6, 2004	
GP	EZ	2004/0087564	A1	Wright et al.	May 6, 2004	
GP	FA	2004/0091527	A1	Curatolo et al.	May 13, 2004	
GP	FB	2004/0092460	A1	Dumic et al.	May 13, 2004	
GP	FC	2004/0101557	A1	Gibson et al.	May 27, 2004	
GP	FD	2004/0109894	A1	Shefer et al.	June 10, 2004	
GP	FE	2004/0121966	A1	Li et al.	June 24, 2004	
GP	FF	2004/0132673	A1	Suh et al.	July 8, 2004	
GP	FG	2004/0138149	A1	Li et al.	July 15, 2004	
GP	FH	2004/0138150	A1	Santi et al.	July 15, 2004	
GP	FI	2004/0170617	A1	Finegold	September 2, 2004	

Examiner Signature	<i>E. Ascher</i>	Date Considered	6/19/06
--------------------	------------------	-----------------	---------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

+

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

4

of

6

Application Number

10/802.282

Filing Date

March 17, 2004

First Named Inventor

Woo et al.

Group Art Unit

1623

Examiner Name _____

Unassigned

Attorney Docket Number

223467


[illegible]

G. Pescher

5719/06

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/802,282
				Filing Date	March 17, 2004
				First Named Inventor	Woo et al.
				Group Art Unit	1623
				Examiner Name	Unassigned
Sheet	5	of	6	Attorney Docket Number	223467

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
cy	GB	CA	1,314,876		Pfizer Inc.	03/23/1993		
cy	GC	CN	1093370	A	Jicai Medicine Research Inst B	10/12/1994		+
cy	GD	CN	1114960	A	Jicai Medicine Inst Beijing	01/17/1996		+
cy	GE	CN	1123279	A	Shen Jiaxiang	05/29/1996		+
cy	GF	CN	1161971	A	Shijiazhuang Pharmaceutical GR	10/15/1997		+
cy	GG	CN	1205338	A	Liu Wanzhong	01/20/1999		+
cy	GH	EP	0101186	A1	Pfizer Inc.	02/22/1984		
cy	GI	EP	0284203	A2	Beecham Group PLC	09/28/1988		
cy	GJ	EP	0298650	B1	Pfizer Inc.	01/11/1989		
cy	GK	EP	0307128	B1	Pfizer Inc.	03/15/1989		
cy	GL	EP	0445743	B1	Pliva Farmaceutska et al.	09/11/1991		
cy	GM	EP	0467331	A1	Pliva Farmaceutska et al.	01/22/1992		
cy	GN	EP	0677530	B1	Pliva, farmeceutska et al.	10/18/1995		
cy	GO	EP	0827965	A2	Astur-Pharma, S.A.	06/03/1998		
cy	GP	EP	0879823	B1	Hovione Inter Ltd.	11/25/1998		
cy	GQ	EP	0941999	A2	Hovione Inter Ltd.	09/15/1999		
cy	GR	EP	0984020	B1	Apotex, Inc.	07/24/2002		
cy	GS	EP	1103558	B1	Astur-Pharma, S.A.	06/25/2003		
cy	GT	EP	1227102	B1	Alembic Limited	03/31/2004		
cy	GU	EP	1234833	A2	Astur-Pharma, S.A.	03/12/2003		
cy	GV	EP	1400528	A1	Alembic Limited	03/24/2004		
cy	GW	GB	2395482	A	Jubilant Organosys Limited	05/26/2004		
cy	GX	JP	01038096	A	Pfizer Inc.	02/08/1989		+
cy	GY	JP	01193292	A	Pfizer Inc.	08/03/1989		+
cy	GZ	JP	02083326	A	Pfizer Inc.	02/23/1990		+
cy	HA	JP	05132497	A	Pliva Pharmaceut & Chem Works	05/28/1993		+
cy	HB	JP	06184186	A	Pliva Pharmaceut & Chem Works	05/07/1994		+
cy	HC	JP	08041058	A	Pliva Pharmaceut	02/13/1996		+
cy	HD	JP	10072482	A	Astur Pharma SA	03/17/1998		+
cy	HE	JP	10316699	A	Hovione Inter Ltd.	12/02/1998		+
cy	HF	JP	41132276	A	Hovione Inter Ltd.	11/24/1999		+
cy	HG	JP	2000219697	A	Pfizer Prod. Inc.	08/08/2000		+

Examiner Signature	/Elli Peselev/	Date Considered	05/19/2006
--------------------	----------------	-----------------	------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 +An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → +

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
Application Number		10/802,282			
Filing Date		March 17, 2004			
First Named Inventor		Woo et al.			
Group Art Unit		1623			
Examiner Name		Unassigned			
Attorney Docket Number		223467			
Sheet	6	of	6		

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No ⁺⁺
GP	HH	JP	2001187797	A	Astur Pharma SA	07/10/2000		+
GP	HI	WO	89/00576	A1	Pfizer Inc.	01/26/1989		
GP	HJ	WO	94/26758	A1	Pfizer Inc.	11/24/1994		
GP	HK	WO	95/30422	A1	Pfizer Inc.	11/16/1995		
GP	HL	WO	96/19489	A1	Russinsky Limited	06/21/1996		
GP	HM	WO	98/05674	A1	Russinsky Limited	02/12/1998		
GP	HN	WO	98/33482	A1	Abbott Laboratories	08/06/1998		
GP	HO	WO	99/32500	A2	Biochemie S.A.	07/01/1999		
GP	HP	WO	99/58541	A2	Biochemie S.A.	11/18/1999		
GP	HQ	WO	00/32203	A1	Teva Pharmaceutical Industries	06/08/2000		
GP	HR	WO	01/87912	A1	Ercros Indus.	05/17/2000		
GP	HS	WO	02/085898	A1	Hanmi Pharm. Co., Ltd.	10/31/2002		
GP	HT	WO	02/087596	A2	Culic, Ognjen et al.	11/07/2002		
GP	HU	WO	02/094843	A1	Pfizer Products Inc.	11/28/2002		
GP	HV	WO	02/09640	A2	Singh et al.	02/07/2002		
GP	HW	WO	03/018031	A2	Pfizer Products Inc.	03/06/2003		
GP	HX	WO	03/020290	A1	Pechere et al.	03/13/2003		
GP	HY	WO	03/032922	A2	Teva Pharmaceutical Industries	04/24/2003		
GP	HZ	WO	03/063838	A1	Pfizer Products Inc.	08/07/2003		
GP	IA	WO	03/070254	A1	Sympore GmbH	08/28/2003		
GP	IB	WO	03/082889	A1	Kim et al.	10/09/2003		
GP	IC	WO	03/102009	A1	Turchetta et al.	12/11/2003		
GP	ID	WO	2004/000865	A1	Sandoz GmbH	12/31/2003		
GP	IE	WO	2004/009608	A2	Pliva, d.d.	01/29/2004		
GP	IF	WO	2004/035063	A1	Sandoz GmbH	04/29/2004		
GP	IG	WO	2004/083227	A1	Apotex Inc.	09/30/2004		

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No ⁺⁺
GP	IH	PFIZER LABS, Division of Pfizer Inc., NY, NY 10017, "Zithromax," 70-5191-00-8 (October 2003)		

Examiner Signature	/Elli Peseelev/	Date Considered	05/19/2006
--------------------	-----------------	-----------------	------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺⁺An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).



Substitute for Form 449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 10/802,282
Filing Date March 17, 2004
First Named Inventor Woo et al.
Group Art Unit 1623
Examiner Name Unassigned
Attorney Docket Number 223467

U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
cy	AA	4,328,334	A	KOBREHEL et al.	May 4, 1982	
cy	AB	4,474,768	A	BRIGHT	Oct. 2, 1984	
cy	AC	4,517,359	A	KOBREHEL et al.	May 14, 1985	
cy	AD	5,605,889	A	CURATOLO et al.	Feb. 25, 1997	
cy	AE	6,013,778	A	HEGGIE et al.	Jan. 11, 2000	
cy	AF	6,245,903	B1	KARIMIAN et al.	Jun. 12, 2001	
cy	AG	6,268,489	B1	ALLEN et al.	Jul. 31, 2001	
cy	AH	6,365,574	B2	SINGER et al.	Apr. 2, 2002	
cy	AI	2001/0047089	A1	ARONHIME et al.	Nov. 29, 2001	
cy	AJ	2002/0007049	A1	SINGER et al.	Jan. 17, 2002	
cy	AK	2003/0139583	A1	SINGH et al.	Jul. 24, 2003	
cy	AL	2003/0143259	A1	ROY et al.	Jul. 31, 2003	
cy	AM	2003/0162730	A1	LI et al.	Aug. 28, 2003	
cy	AN	2003/0176369	A1	TENENGAUZER et al.	Sep. 18, 2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
cy	AO	EP	1 103 558	B1	Astur-Pharma, S.A.	May 30, 2001		
cy	AP	WO	00/32203	A1	TEVA PHARMACEUTICALS USA, INC.	June 8, 2000		
cy	AQ	WO	02/07736	A1	CADILA PHARMACEUTICALS LIMITED et al.	Jan. 31, 2002		
cy	AR	WO	02/087596	A3	PLIVA d.d.	Nov. 7, 2002		

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
cy	AS	PFIZER LABS, Division of Pfizer Inc., NY, NY 10017, "Zithromax," 69-4763-00-7 (October 2002)		
cy	AT	PFIZER LABS, Division of Pfizer Inc., NY, NY 10017, "Zithromax," 70-5179-00-1 (October 2002)		

Examiner Signature

/Elli Peselev/

Date Considered

05/19/2006

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).